Physician profile
Christopher Yang
NPI 1083823785
$8,392.97
in general payments reported to CMS, 2019-2025
35 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $478 · 2021: $1,084 · 2022: $1,326 · 2023: $771 · 2024: $1,475 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,329 · Travel and Lodging: $1,151 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.98 |
| Travel and Lodging | $1,151.16 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $3,413.88 | 2019-2025 | Titan, Porges Coloplast |
| Teleflex LLC | $2,064.71 | 2020-2025 | Urolift, Barrigel |
| Verathon INC. | $500.00 | 2024 | Npd Clinical Study |
| Boston Scientific Corporation | $360.76 | 2019-2023 | Spaceoar Vue System - 10ml |
| Endo Pharmaceuticals INC. | $184.30 | 2019-2024 | Xiaflex, Aveed, Edex |
| 180 Medical, INC. | $171.62 | 2020-2024 | |
| Biotissue Holdings INC. | $165.09 | 2025 | |
| Endo USA, INC. | $150.10 | 2024-2025 | Xiaflex, Aveed |
| Janssen Scientific Affairs, LLC | $137.65 | 2024 | Tremfya |
| Axonics, INC. | $128.04 | 2020 | |
| Novo Nordisk INC | $126.79 | 2024-2025 | Ozempic, Rivfloza |
| Olympus America INC. | $106.47 | 2024-2025 | Itind System |
| Antares Pharma, INC. | $86.58 | 2023-2025 | Xyosted, Tlando |
| Innovation Technologies INC | $70.60 | 2025 | Irrisept |
| Rigicon,INC. | $62.38 | 2023 | Rigi10 Malleable Penile Prosthesis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $56.22 | 2025 | |
| Valencia Technologies Corporation | $55.75 | 2025 | Ecoin Device Kit |
| Tolmar, INC. | $54.15 | 2024-2025 | Jatenzo |
| Neotract INC. | $48.74 | 2020 | |
| Accord Healthcare, INC. | $47.04 | 2024 | |
| Allergan, INC. | $45.59 | 2019-2022 | |
| Clarus Therapeutics INC. | $41.21 | 2021 | |
| Angiodynamics, INC. | $40.17 | 2022-2025 | Nanoknife |
| Ferring Pharmaceuticals INC. | $35.83 | 2019 | |
| Medtronic, INC. | $34.44 | 2025 | Interstim |
| Myriad Genetic Laboratories, INC. | $32.74 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $25.06 | 2024 | Embozene, Varian Cryocare Touch System |
| Travere Therapeutics, INC. | $23.59 | 2021 | |
| Janssen Biotech, INC. | $22.77 | 2025 | Carvykti, Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $22.23 | 2025 | |
| Halozyme INC | $20.91 | 2023 | |
| Myovant Sciences INC. | $20.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.25 | 2024 | |
| Astellas Pharma US INC | $11.05 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.